Project Grant R21AI185846
Award Date
8/5/24
Completion Date
6/30/26
Dollars Obligated
$354K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70125, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $847,141 to investigate the role of HIV-1 integrase (IN) in virion morphogenesis and target it with novel allosteric integrase inhibitors. The research aims to delineate the sequence and structural features of viral RNA recognized by HIV-1 IN and determine cryo-EM structures of IN tetramers bound to cognate viral RNA...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,399,467 to The Johns Hopkins University to investigate the cellular and molecular mechanisms by which integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) leads to weight gain, particularly in women. The research aims to: 1) define the molecular pathways by...
This Project Grant award of $227,588 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop protein-based proteolysis targeting chimeras (BIOPROTACs) to degrade the HIV-1 Rev protein. The goal is to create a novel therapy that leverages the cell's own protein degradation machinery to target this critical viral protein, which is difficult to inhibit using traditional small...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to comprehensively investigate the extent and impact of transmitted and acquired HIV drug resistance in Kenya as the country transitions to widespread use of dolutegravir-based antiretroviral therapy. The $645,900 award, with a project period from September 2024 to July 2029, will fund a prospective study to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $208,575 to develop an ionic liquid-based nanoemulsion containing a combination of antiretroviral drugs for the oral and transdermal treatment of HIV infection. The goal is to improve the oral bioavailability and skin permeability of the integrase inhibitor dolutegravir and the non-nucleoside reverse...
The National Institute on Drug Abuse (NIDA) awarded a $687,416 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The grant supports research to develop therapeutically effective latency-promoting agents (LPAs) that can "block" HIV reactivation and "lock" HIV in a silenced state, even in the presence of addictive substances, for people living...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616 to Emory University to develop virus-like particles (VLPs) for use in HIV-1 cure strategies. The key products and services to be delivered under this 18-month project include: Using VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, as part of a "shock and kill" strategy to...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $919,501 to Emmune Inc. to develop a non-viral gene therapy platform for delivering the ECD4-IG therapeutic protein as a practical approach for lifelong suppression of HIV replication. The goal is to establish a 'functional cure' for HIV through a single intramuscular injection that can sustain...